Sildenafil Tablet, Film Coated
Product Images NDC 71335-1649

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-1649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier curve chart depicting estimated cumulative mortality rates over time for three groups labeled as High dose, Medium dose, and Low dose. The y-axis represents mortality rate (%) and the x-axis represents time units. The number of subjects at risk is shown above the chart for each group at multiple time points.*

FDA Label Image

Figure3 (Figure3)

A chart displaying the fold change and 90% confidence intervals for various interacting drugs relative to the interacting drug alone. The drugs listed include Acenocoumarol, Aspirin, Atorvastatin, Bosentan, multiple doses of Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. The rightmost column shows recommendations regarding dose adjustments, mostly indicating no dose adjustment, except Ritonavir where coadministration is not recommended.*

FDA Label Image

Figure4 (Figure4)

A line graph showing the change from baseline over three study weeks (Weeks 4, 8, and 12). It compares the effects of TID dosages of Tadalafil 40 mg, Placebo, Sildenafil 80 mg, and Sildenafil 30 mg, with mean values and error bars displayed for each group at each time point.*

FDA Label Image

Figure5 (Figure5)

A scatter plot with horizontal error bars comparing placebo and Sildenafil 20 mg three times daily on placebo-corrected change in 6-minute walk distance. Data is stratified by baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary artery pressure, and pulmonary vascular resistance index. The x-axis shows change in distance ranging from -20 to 40 meters.*

FDA Label Image

Figure6 (Figure6)

A line graph comparing the percentage without a clinically worsening event over time between Sildenafil and placebo groups. The x-axis represents days from randomization, and the y-axis represents the percentage without worsening. Two lines are shown, with Sildenafil maintaining a higher percentage over the period compared to placebo.*

FDA Label Image

Figure7 (Figure7)

A line chart showing mean changes from baseline in meters over a 12-week study period for Sildenafil doses of 1 mg, 5 mg, and 20 mg, each administered three times daily (TID). The y-axis measures change from baseline in meters, and the x-axis represents study weeks 4, 8, and 12. Data points include error bars indicating standard error for each treatment at each visit.*

FDA Label Image

Structure (Structure)

Chemical structure of Sildenafil, the active ingredient in the product. The diagram shows its molecular framework with rings and functional groups typical for this compound used in oral tablet form.*

FDA Label Image

Camber1 (Camber1)

FDA Label Image

Camber2 (Camber2)

FDA Label Image

Fig2

A chart depicting the fold change and 90% confidence interval of the interaction between Sildenafil and various drugs, showing changes in AUC and Cmax relative to Sildenafil alone. The graph includes a recommendation column indicating whether dose adjustment is needed for coadministration with each drug.*

FDA Label Image

Image1 (Image1)

A line plot showing the mean change from baseline in meters on the Y-axis over a 12-week study period marked on the X-axis at weeks 4, 8, and 12. The plot compares three Sildenafil doses (1 mg, 5 mg, and 20 mg taken three times daily) with distinct markers, including corresponding standard error bars for each treatment at the specified time points.*

FDA Label Image

Label Image (Lbl713351649)

Sildenafil Citrate 20 mg film-coated tablet label by Bryant Ranch Prepack, containing 10 tablets. The label includes a comparison to Revatio 20 mg tablet by Hetero Labs Limited. It displays storage instructions at 20°-25°C (68°-77°F), a warning to keep out of reach of children, and features an NDC number 71335-1649-1. The label also shows a lot number and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.